
==== Front
Oncologist
Oncologist
oncolo
The Oncologist
1083-7159
1549-490X
Oxford University Press US

38821519
10.1093/oncolo/oyae108
oyae108
Clinical Trial Results
AcademicSubjects/MED00010
Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results
Xia Zu-Guang Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Lv Fang-Fang Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Zhang Qun-Ling Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Liu Yi-Zhen Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Zhang Sheng-Jian Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Liu Chang Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Li Xiao-Qiu Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Wen Yu Department of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, People’s Republic of China

Wu Zhen-Yu Department of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, People’s Republic of China

Hong Xiao-Nan Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Guo Ye Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Cao Jun-Ning Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Corresponding author: Jun-Ning Cao, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China (cao_junning@126.com)
Corresponding author: Ye Guo, Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200123, People’s Republic of China (pattrickguo@gmail.com).
9 2024
31 5 2024
31 5 2024
29 9 819e1223
04 1 2024
19 4 2024
© The Author(s) 2024. Published by Oxford University Press.
2024
The data published online to support this summary are the property of the authors. Please contact the authors about reuse rights of the original data.
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Abstract

Background

Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL).

Methods

Patients received PLD, cyclophosphamide, vincristine/vindesine, plus prednisone every 3 weeks for up to 6 cycles. The primary endpoint was the objective response rate at the end of treatment (EOT).

Results

From September 2015 to January 2017, 40 patients were treated. At the EOT, objective response was achieved by 82.5% of patients, with 62.5% complete response. As of the cutoff date (September 26, 2023), median progression-free survival (mPFS) and overall survival (mOS) were not reached (NR). The 2-year, 5-year, and 8-year PFS rates were 55.1%, 52.0%, and 52.0%. OS rate was 80.0% at 2 years, 62.5% at 5 years, and 54.3% at 8 years. Patients with progression of disease within 24 months (POD24) had worse prognosis than those without POD24, regarding mOS (41.2 months vs NR), 5-year OS (33.3% vs 94.4%), and 8-year OS (13.3% vs 94.4%). Common grade 3-4 adverse events were neutropenia (87.5%), leukopenia (80.0%), anemia (17.5%), and pneumonitis (17.5%).

Conclusion

This combination had long-term benefits and manageable tolerability, particularly with less cardiotoxicity, for aggressive PTCL, which might provide a favorable benefit-risk balance.

ClinicalTrials.gov Identifier

Chinese Clinical Trial Registry, ChiCTR2100054588; IRB Approved: Ethics committee of Fudan University Shanghai Cancer Center (Date 2015.8.31/No. 1508151-13.

This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas.

chemotherapy
first-line treatment
pegylated liposomal doxorubicin
peripheral T-cell lymphomas
==== Body
pmcLessons Learned

With an 8-year follow-up, the PLD-containing CHOP regimen had long-term benefits in PTCL, with 8-year PFS and OS rates of 52.0% and 54.3%.

The PLD-containing CHOP regimen was associated with less cardiotoxicity compared with CHOP/CHOP-like regimens and was generally manageable.

Based on these impressive long-term results, the combination regimen may serve as a reasonable first-line approach with a favorable benefit-risk balance for aggressive PTCL.

Discussion

PTCL is a rare and heterogeneous hematologic malignancy, with dismal outcomes. Despite much efforts (eg, targeted therapy and immunotherapy) in improving efficacy, the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens remain the preferred first-line therapy option for the general population with PTCL. Nevertheless, doxorubicin is associated with cumulative and dose-dependent cardiotoxicity, resulting in increased risks of mortality. PLD is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. With the goal of getting a favorable benefit-risk balance and based on our phase 1 dose-escalation study, we designed a prospective, single-arm, phase 2 study to evaluate the efficacy and safety of 40 mg/m2 PLD as an alternative for doxorubicin in CHOP regimen for aggressive PTCL.

From September 2015 to January 2017, 40 patients received at least one dose of protocol therapy. At the time of data cutoff (September 26, 2023), 30 (75.0%) patients completed the planned treatment schedule. At the end of treatment (EOT), objective response was achieved in 82.5% (95% CI, 67.2-92.7) of patients, with 62.5% complete response and 20.0% partial response (PR). Median duration of response (DoR) of responders was not reached, with a 2-year DoR rate of 58.7% (95% CI, 44.6-77.2), both 5-year and 8-year DoR rates of 55.8% (95% CI, 41.6-74.7). With a median follow-up of 7.4 years (95% CI, 7.1-7.9), mPFS was NR (Figure 1A). The estimated PFS rate of the overall population was 55.1% (95% CI, 40.5-74.9) at 2 years, and both 52.0% (95% CI, 37.5-72.2) at 5 and 8 years, respectively. Based on 18 deaths, the median OS was also NR due to insufficient events (Figure 1B), with 2-year, 5-year, and 8-year OS rates of 80.0% (95% CI, 68.5-93.4), 62.5% (95% CI, 49.2-79.5), and 54.3% (95% CI, 40.7-72.5). The prognostic significance of progression of disease within 24 months (POD24) has been identified for patients with newly diagnosed PTCL. Here, POD24 was observed in 15 (45.5%) of 33 patients and was found to be associated with poor OS (non-POD24 vs POD24: NR vs 41.2 months; P < .001). Treatment-related adverse events of any grade occurred in all 40 (100%) patients, with ≥grade 3 events being reported in 36 (90%) and serious events in 6 (15%). From baseline to the EOT, 30 patients exhibited different degrees of left ventricular ejection fraction (LVEF) decline, with a mean of 7.2% (range, 1.0%-19.0%; SD, 4.3%). The LVEF decline of ≥10% was observed in 6 patients (15%), of which 2 (5%) had a resting LVEF of <50%. Besides, 13 (43.3%) patients displayed a subsequent recovery of LVEF.

Figure 1. Kaplan-Meier curves in the overall population. (A) Progression-free survival. PFS analysis was performed by censoring patients who received non-study antitumor therapies prior to progression at the time of starting new antitumor therapies. With 16 disease progression or death occurring, the median PFS was not reached at the data cutoff, with estimated PFS rates of 55.1% (95% CI, 40.5-74.9) at 2 years, and both 52.0% (95% CI, 37.5-72.2) at 5 and 8 years. (B) Overall survival. Based on 18 deaths, the median OS of all patients was not reached due to insufficient events, with 2-year, 5-year, and 8-year OS rates of 80.0% (95% CI, 68.5-93.4), 62.5% (95% CI, 49.2-79.5), and 54.3% (95% CI, 40.7-72.5).

Trial Information	
Disease	Peripheral T-cell lymphoma	
Stage of disease/treatment	Stage 1-4/newly diagnosed	
Prior therapy	None	
Type of study	Prospective, open-label, single-arm, phase 2 study	
Primary endpoint	Objective response rate (ORR) at the EOT	
Secondary endpoints	Progression-free survival (PFS), overall survival (OS), DoR, and safety	

Additional details of endpoints or study design

Study design

The prospective, open-label, single-arm, single-center, phase 2 study (Chinese Clinical Trial Registry, ChiCTR2100054588) was carried out to evaluate the efficacy and safety of PLD, cyclophosphamide, vincristine/vindesine, and prednisone in subjects with newly diagnosed aggressive PTCL. This study was performed following the Declaration of Helsinki and clinical practice guidelines and was approved by the ethics committee of Fudan University Shanghai Cancer Center (number, 1508151-13). All included subjects were fully aware of the protocol and submitted written informed consent.

Patient eligibility

Patients aged 18-75 years with histologically confirmed treatment-naïve aggressive PTCL (except natural killer/T-cell lymphoma) according to the World Health Organization classification were eligible for this study. Additional criteria of enrollment included an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, a life expectancy of at least 6 months, at least one measurable lesion, and baseline left ventricular ejection fraction (LVEF) of ≥50%. Patients were also required to have adequate organ function of bone marrow, liver, and kidney.

Patients with primary or secondary central nervous system involvement, other malignant tumors (except cured cervical cancer or basal cell carcinoma of the skin), heart disease, previous severe chronic skin diseases, poorly controlled hypertension or diabetes, severe active infection, previous allergic asthma or severe allergic disease, or mental disorders were ineligible for this study. Patients who had received organ transplants, as well as pregnant or lactating females were also excluded.

Procedures

Eligible patients were treated with intravenous (i.v.) PLD (Duomeisu, 40 mg/m2, CSPC Ouyi Pharmaceutical Group Co., Ltd.), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2, maximum 2 mg/m2) or vindesine (2 mg/m2, maximum 4 mg/m2) on day 1, plus oral prednisone (50 mg, twice-daily) on days 1-5 of each cycle. Treatment cycles were repeated every 3 weeks for up to 6 cycles, until intolerable toxicity, loss of tumor response, or death. Due to a transient shortage of vincristine in China, some patients were administered vindesine instead of vincristine. Suspension, discontinuation, and dose reduction of chemotherapy drugs were allowed according to the severity of any adverse events (AEs) that occurred in the previous course. Antiemetic therapy with 5-hydroxytryptamine 3 receptor antagonists was routinely administered. Prophylactic granulocyte-colony stimulating factors (G-CSF), thrombopoietin rather than interleukin-11, and component transfusion were allowed. The use of dexrazoxane was prohibited. Besides, consolidation with autologous stem cell transplantation (auto-SCT) after first-line therapy or maintenance therapy after objective response from first-line therapy was not allowed.

Treatment response was assessed at baseline and the end of cycles 2, 4, and 6 using enhanced computed tomographic (CT) scans according to the standardized response criteria for NHLs.1 AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Prespecified AE of special interest was cancer therapy-related cardiac dysfunction (CTRCD), which was defined as a resting LVEF <50% and an absolute reduction in LVEF ≥10%, or the occurrence of signs or symptoms of congestive heart failure according to previous studies.2 LVEF was assessed by radionuclide angiography at screening and at the end of cycle 2, cycle 4, and cycle 6. In long-term follow-up, complete blood count, liver and kidney function, serum lactate dehydrogenase (LDH), and imaging examination by enhanced CT scan were performed every 3 months during the first 2 years after completion of study treatment, and every 6 months thereafter until patients experienced disease progression, death, or the initiation of a new treatment, whichever came first.

Endpoints

The primary endpoint was the ORR at the EOT, which was defined as the proportion of patients who achieved complete response (CR; complete response or unconfirmed complete response) or PR at the EOT as per the Standardize response criteria for non-Hodgkin’s lymphomas: International Working Group.1 Secondary endpoints included PFS (defined as the time from enrollment to disease progression or death from any cause), OS (defined as the time from enrollment to death from any cause), DoR (defined as the time from onset of response to disease progression), and safety.

The outcome according to POD24 status was evaluated as a post hoc exploratory endpoint. POD24 was defined as the first documented relapse or progression of the disease within 24 months after initiation of treatment. Patients were not evaluable for POD24 if they were censored or had died within 24 months without progression of the disease.

Statistical analysis

The sample size calculation of this phase 2 study was based on ORR considerations. According to the historical ORR data (54.4%) of CHOP regimen in Chinese patients with PTCL,3 it is assumed that an ORR of 55% or less is considered unacceptable in this study. We estimated that a target ORR of 77% with PLD plus COP regimen is considered to have statistical significance, based on the mean value of maximum historical ORR (75% and 79%) with CHOP regimen.4,5 With this assumption and a dropout rate of 10%, approximately 40 patients would provide a power of 80% at a 2-sided type I error of 5%.

Efficacy was primarily analyzed in the full analysis set, which comprised all patients who received at least one dose of chemotherapy drugs. Safety was analyzed in the safety analysis set, which comprised all patients who received at least one dose of chemotherapy drugs. The ORR was summarized descriptively, along with the exact 95% CI. The Clopper-Pearson method was used to calculate the 95% CI for ORR. The PFS, OS, and DoR were estimated using Kaplan-Meier curves. PFS analysis was performed by censoring patients who received non-study antitumor therapies prior to progression at the time of starting new antitumor therapies. For the analysis of OS, data for patients who were alive or who were lost to follow-up were censored at the time of the last contact. The OS of the POD24 group and the non-POD24 group were compared using the log-rank test. Safety was analyzed descriptively. All analyses were performed with R Statistical Language (version 4.2.0), and the significance level was set at P < .05.

Drug Information	
Drug 1	
 Generic/working name	Pegylated liposomal doxorubicin	
 Company name	CSPC Ouyi Pharmaceutical Group Co., Ltd.	
 Drug type	Cytotoxic agents	
 Drug class	Anthracyclines	
 Dose	40	
 Unit	mg/m2	
 Route	i.v.	
 Schedule of administration	Administered on day 1 every 3 weeks for up to 6 cycles	
Drug 2	
 Generic/working name	Cyclophosphamide	
 Company name	Baxter	
 Drug type	Cytotoxic agents	
 Drug class	Alkylating agents	
 Dose	750	
 Unit	mg/m2	
 Route	i.v.	
 Schedule of administration	Administered on day 1 every 3 weeks for up to 6 cycles	
Drug 3	
 Generic/working name	Vincristine or vindesine	
 Company name	Vincristine (Shenzhen Main Luck Pharmaceuticals Inc.)
Vindesine (Hangzhou Minsheng Pharmaceutical Co., Ltd.)	
 Drug type	Cytotoxic agents	
 Drug class	Vinca alkaloids	
 Dose	Vincristine (1.4 mg/m2, maximum 2 mg/m2)
Vindesine (2 mg/m2, maximum 4 mg/m2)	
 Unit	mg/m2	
 Route	i.v.	
 Schedule of administration	Administered on day 1 every 3 weeks for up to 6 cycles	
Drug 4	
 Generic/working name	Prednisone	
 Company name	Tianjin Jinjin Pharmaceutical Co., Ltd.	
 Drug type	Glucocorticoid	
 Drug class	Corticosteroids	
 Dose	50	
 Unit	mg	
 Route	Oral	
 Schedule of administration	Administered on days 1-5 every 3 weeks for up to 6 cycles	

Patient Characteristics	
Number of patients	
 Male	25 (62.5%)	
 Female	15 (37.5%)	
Stage	
 1	3 (7.5%)	
 2	9 (22.5%)	
 3	10 (25.0%)	
 4	18 (45.0%)	
Age (years), median (range)	55.0 (47.8-61.0)	
Number of prior systemic therapies: median	0	
Performance status: ECOG	
	0: 11 (27.5%)	
	1: 29 (72.5%)	
	2: 0	
	3: 0	
	4: 0	

Cancer types or histologic subtypes	Number	
Peripheral T-cell lymphoma-not otherwise specified	19 (47.5%)	
Angioimmunoblastic T-cell lymphoma	9 (22.5%)	
ALK-positive anaplastic large-cell lymphoma	6 (15.0%)	
ALK-negative anaplastic large-cell lymphoma	5 (12.5%)	
Subcutaneous panniculitis-like T-cell lymphoma with systemic involvement	1 (2.5%)	

Primary Assessment Method	
Number of patients screened	42	
Number of patients enrolled	41	
Number of patients evaluable for toxicity	40	
Number of patients evaluated for efficacy	40	
Evaluation method	Other (standardize response criteria for non-Hodgkin’s lymphomas: International Working Group)	
Response assessment	
 CR	25 (62.5%)	
 PR	8 (20.0%)	
 SD	2 (5.0%)	
 PD	4 (10.0%)	
 Not evaluable	1 (2.5%)	
Median duration assessment	
 PFS	2-year PFS rate: 55.1% (95% CI: 40.5-74.9)
5-year PFS rate: 52.0% (95% CI: 37.5-72.2)
8-year PFS rate: 52.0% (95% CI: 37.5-72.2)	
 OS	2-year OS rate: 80.0% (95% CI: 68.5-93.4)
5-year OS rate: 62.5% (95% CI: 49.2-79.5)
8-year OS rate: 54.3% (95% CI: 40.7-72.5)	
 Response duration	2-year DoR rate: 58.7% (95% CI: 44.6-77.2)
5-year DoR rate: 55.8% (95% CI: 41.6-74.7)
8-year DoR rate: 55.8% (95% CI: 41.6-74.7)	
Outcomes notes	See Figures 2 and 3. See also Table 1 and Table 2. Treatment-related AEs are described in Table 3. As AEs of special interest related to PLD, mucositis and hand-foot syndrome of any grade were reported in 37.5% (15/40) and 17.5% (7/40) of patients, respectively. Treatment-related AEs leading to treatment discontinuation included pneumonitis (n = 3) and CTRCD (n = 2). No death associated with the combination regimen was observed	

Assessment, Analysis, and Discussion

Completion	Study completed	
Investigator’s assessment	Active but results overtaken by other developments	

Currently, attempts to improve the efficacy of CHOP have been largely unsuccessful, being primarily carried out in single-arm or phase 2 studies.6-9 Despite the observed OS benefit of brentuximab vedotin (BV) plus CHP for CD30-positive PTCL in the ECHELON-2 study,10,11 clinical benefit population was primarily patients with ALCL. So far, the CHOP or a CHOP-like regimen remains the preferred first-line therapy option in PTCL irrespective of biomarker status. To our knowledge, this study represented the first and prospective long-term results for up to 8 years of PLD-containing regimen in patients with newly diagnosed aggressive PTCL. This study yielded an encouraging ORR (82.5%) at the EOT to 6 cycles of the combination regimen, as well as offered long-term survival benefits in this population, with an 8-year PFS rate of 52.0% and an 8-year OS rate of 54.3%. Meanwhile, this combination had a manageable tolerability, particularly with less cardiotoxicity. Based on these impressive long-term results, the combination regimen may serve as a reasonable first-line approach with a favorable benefit-risk balance in treating this disease.

Figure 2. Kaplan-Meier curves of overall survival according to progression of disease within 24 months (POD24) status. Median OS was longer in non-POD24 patients than in POD24 patients (not reached vs 41.2 months; P < .001).

Figure 3. The changes of left ventricular ejection fraction (LVEF) over time from baseline to the end of treatment in 39 with post-treatment LVEF results. From baseline to the end of treatment, 30 patients exhibited different degrees of LVEF decline, with a mean LVEF decline of 7.2% (range, 1.0%-19.0%; SD, 4.3%). The LVEF decline of ≥10% was observed in 6 patients (15.0%), of which 2 (5.0%) patients had a resting LVEF of <50%. Thirteen (43.3%) of 30 patients displayed a subsequent recovery of LVEF.

Table 1. Patient and disease characteristics.

Characteristics	Total (n = 40)	
Age (years), median (IQR)	55.0 (47.8-61.0)	
Age (years), n (%), ≤60/>60	28 (70.0)/12 (30.0)	
Gender, n (%), male/female	25 (62.5)/15 (37.5)	
ECOG performance status, n (%), 0/1	11 (27.5)/29 (72.5)	
Disease stage, n (%)	
 1	3 (7.5)	
 2	9 (22.5)	
 3	10 (25.0)	
 4	18 (45.0)	
Histologic subtypes	
 PTCL-NOS	19 (47.5)	
 AITL	9 (22.5)	
 ALK-positive ALCL	6 (15.0)	
 ALK-negative ALCL	5 (12.5)	
 SPTL with systemic involvement	1 (2.5)	
B symptoms present, n (%)	10 (25.0)	
Increased serum LDH, n (%)	12 (30.0)	
Extranodal sites > 1, n (%)	6 (15.0)	
Bone marrow involvement, n (%)	1 (2.5)	
Bulky disease ≥ 7.5cm, n (%)	2 (5.0)	
Decreased albumin, n (%)	12 (30.0)	
Increased serum β2 microglobulin, n (%)	13 (34.2)	
IPI score, n (%)	
 0-1	19 (47.5)	
 2	18 (45.0)	
 3	3 (7.5)	
PIT score, n (%)	
 0	16 (40.0)	
 1	23 (57.5)	
 2	1 (2.5)	
Modified PIT score, n (%), 0-1/2	32 (80.0)/8 (20.0)	
Abbreviations: PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma; SPTL, subcutaneous panniculitis-like T-cell lymphoma; IQR, interquartile range; LDH, lactate dehydrogenase; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; PIT, Prognostic Index for T-cell lymphoma.

Table 2. Tumor response at the EOT and survival outcomes by histologic subtypes.

	Total (n = 40)	PTCL-NOS (n = 19)	AITL (n = 9)	ALK-positive ALCL (n = 6)	ALK-negative ALCL (n = 5)	SPTL with systemic involvement (n = 1)	
Tumor responses at EOT, n (%)	
 CR	25 (62.5)	9 (47.4)	7 (77.8)	4 (66.7)	4 (80.0)	1 (100.0)	
 PR	8 (20.0)	4 (21.0)	2 (22.2)	1 (16.7)	1 (20.0)	0	
 SD	2 (5.0)	2 (10.5)	0	0	0	0	
 PD	4 (10.0)	3 (15.8)	0	1 (16.7)	0	0	
 NE	1 (2.5)	1 (5.3)	0	0	0	0	
ORR at EOT, n (%, 95% CI)	33 (82.5, 67.2-92.7)	13 (68.4, 43.4-87.4)	9 (100.0, 66.4-100.9)	5 (83.3, 35.9-99.6)	5 (100.0, 47.8-100.0)	1 (100.0, 2.5-100.0)	
Median PFS (months, 95% CI)	NR	22.0 (11.0-NE)	58.6 (9.9-NE)	NR	10.5 (7.4-NE)	NE	
 2-year PFS (%, 95% CI)	55.1 (40.5-74.9)	48.1 (27.4-84.5)	62.5 (36.5-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
 5-year PFS (%, 95% CI)	52.0 (37.5-72.2)	48.1 (27.4-84.5)	50.0 (25.0-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
 8-year PFS (%, 95% CI)	52.0 (37.5-72.2)	48.1 (27.4-84.5)	50.0 (25.0-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
Median OS (months, 95% CI)	NR	NR	65.2 (42.7-NE)	NR	NR	NE	
 2-year OS (%, 95% CI)	80.0 (68.5-93.4)	73.7 (56.3-96.4)	88.9 (70.6-100.0)	83.3 (58.3-100.0)	80.0 (51.6-100.0)	100.0 (100.0-100.0)	
 5-year OS (%, 95% CI)	62.5 (49.2-79.5)	57.9 (39.5-85.0)	55.6 (31.0-99.7)	66.7 (37.9-100.0)	80.0 (51.6-100.0)	100.0 (100.0-100.0)	
 8-year OS (%, 95% CI)	54.3 (40.7-72.5)	52.1 (33.7-80.5)	44.4 (21.4-92.3)	66.7 (37.9-100.0)	60.0 (29.3-100.0)	100.0 (100.0-100.0)	
Median DoR (months, 95% CI)	NR	NR	NR	NR	9.0 (6.1-NE)	NE	
 2-year DoR (%, 95% CI)	58.7 (44.6-77.2)	55.0 (35.0-86.5)	64.8 (39.3-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
 5-year DoR (%, 95% CI)	55.8 (41.6-74.7)	55.0 (35.0-86.5)	51.9 (26.7-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
 8-year DoR (%, 95% CI)	55.8 (41.6-74.7)	55.0 (35.0-86.5)	51.9 (26.7-100.0)	66.7 (37.9-100.0)	40.0 (13.7-100.0)	100.0 (100.0-100.0)	
Abbreviations: PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma; SPTL, subcutaneous panniculitis-like T-cell lymphoma; EOT, end of treatment; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; PFS, progression-free survival; NR, not reached; OS, overall survival; DoR, duration of response.

Table 3. Treatment-related adverse events in all patients (n = 40).

Adverse events	Any grade	Grade 1-2	Grade 3-4	
Total, n (%)	40 (100.0)	4 (10.0)	36 (90.0)	
Hematological toxicity, n (%)	
 Leukopenia	40 (100.0)	8 (20.0)	32 (80.0)	
 Neutropenia	39 (97.5)	4 (10.0)	35 (87.5)	
 Anemia	39 (97.5)	32 (80.0)	7 (17.5)	
 Thrombocytopenia	15 (37.5)	13 (32.5)	2 (5.0)	
 Febrile neutropenia	2 (5.0)	0	2 (5.0)	
Non-hematological toxicity, n (%)	
 Alopecia	28 (70.0)	28 (70.0)	0	
 Hypoalbuminemia	21 (52.5)	21 (52.5)	0	
 Pneumonitis	21 (52.5)	14 (35.0)	7 (17.5)	
 ALT increased	21 (52.5)	19 (47.5)	2 (5.0)	
 AST increased	19 (47.5)	19 (47.5)	0	
 Pyrexia	19 (47.5)	19 (47.5)	0	
 Mucositis	15 (37.5)	11 (27.5)	4 (10.0)	
 GGT increased	14 (35.0)	14 (35.0)	0	
 Hyperglycemia	12 (30.0)	12 (30.0)	0	
 Fatigue	11 (27.5)	11 (27.5)	0	
 Cough	11 (27.5)	11 (27.5)	0	
 Hyperbilirubinemia	8 (20.0)	7 (17.5)	1 (2.5)	
 Hand-foot syndrome	7 (17.5)	6 (15.0)	1 (2.5)	
 Anorexia	7 (17.5)	7 (17.5)	0	
 Nausea	6 (15.0)	6 (15.0)	0	
 Hyperuricemia	5 (12.5)	5 (12.5)	0	
 Diarrhea	5 (12.5)	5 (12.5)	0	
 Constipation	4 (10.0)	4 (10.0)	0	
 Rash	4 (10.0)	4 (10.0)	0	
 Vomiting	3 (7.5)	3 (7.5)	0	
 Abdominal distension	3 (7.5)	3 (7.5)	0	
 Creatinine increased	3 (7.5)	3 (7.5)	0	
 Allergic reaction	3 (7.5)	3 (7.5)	0	
 Upper respiratory infection	3 (7.5)	3 (7.5)	0	
 Skin hyperpigmentation	2 (5.0)	2 (5.0)	0	
 Skin infection	2 (5.0)	2 (5.0)	0	
 Edema limbs	2 (5.0)	1 (2.5)	1 (2.5)	
 Bullous dermatitis	1 (2.5)	0	1 (2.5)	
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase.

Outcomes with standard CHOP or CHOP-like regimen in PTCL are poor, with an ORR of 49.0%-75.7%, PFS rates of approximately 35% at 2 years and 30.4%-43% at 5 years, and OS rates of approximately 50% at 2 years and 38.5%-48.8% at 5 years.6,12-15 By contrast, our combination regimen yielded a numerically superior ORR (82.5%), 2-year/5-year PFS (55.1% and 52.0%), 2-year OS (80.0%), and 5-year OS (62.5%) to these CHOP/CHOP-like regimens in a similar population. Additionally, although our OS data at 5 years (62.5%) were similar to the historical maximum 5-year OS rate (61%) observed from the CHOP regimen in the ECHELON-2 study,11 OS rate of up to 54.3% at 8 years and long tail in Kaplan-Meier curve further demonstrated the durable OS benefit with our modified CHOP regimen. Particularly, patients who achieved a CR at the EOT had impressive survival with an 8-year PFS and OS rates of 62.5% and 66.5%, reinforcing the potential benefit of our regimen. Even compared to a more aggressive approach with auto-SCT in the NLG-T-01 study (ORR, 82%),16 our ORR data were comparable. More notably, our regimen seems favorable over this aggressive approach with auto-SCT,16 as evidenced by the better 5-year PFS (52.0% vs 44%) and OS (62.5% vs 51%), especially when considering that no patients received consolidation with auto-SCT in our study. Besides, only a few (7.5%) patients received subsequent therapy with auto-SCT or PD-1 inhibitor while no underwent subsequent therapy with BV or allo-SCT or any consolidation/maintenance therapy further highlighted the fact that the observed long-term survival benefit was primarily attributed to our first-line regimen. Interestingly, the survival curve began to plateau after 2 years and remained flat until 8 years, the long tail in the survival curve further confirmed the robust efficacy of our regimen.

Regarding the outcomes according to histologic subtypes, the pattern of survival was consistent with previous findings that ALK-positive ALCL was associated with better outcomes than other subtypes.17 Similar to previous studies,18-20 we also revealed that patients with POD24 were associated with poor prognosis. Additionally, in contrast to previous studies in which nearly two-thirds of patients presented with POD24,18-20 only 45.5% of patients achieved POD24 with our combination treatment, further highlighting its relative effectiveness.

In terms of toxicity, compared to the CHOP regimen, our regimen showed a higher incidence of grade 3-4 neutropenia (87.5% vs 41%) and PLD-associated toxicities (eg, mucositis, hand-foot syndrome, and pneumonitis), but lower grade 3-4 febrile neutropenia (5% vs 29%),13 grade 2 alopecia (35.7% vs 92%),21 or other grade 3-4 non-hematological AEs (eg, nausea and vomiting).10,22 Nevertheless, the high incidence of pneumonitis here might be attributed to the high dose of PLD (40 mg/m2), the immune imbalance caused by neutropenia, and the use of G-CSF in our study. Our regimen also exhibited superior cardiac safety to the CHOP/CHOP-like regimen, with a lower proportion of patients experiencing an LVEF decline of ≥10% to a final LVEF of <50% (5.0% vs 22%-36%).23-25 It should be emphasized that the LVEF was assessed by radionuclide angiography here. There is evidence that radionuclide angiography has higher reproducibility than echocardiography in assessing global LVEF, and is more accurate in patients with a slight or moderate reduction in LVEF.26 Importantly, although 90% of our patients experienced grade 3-4 AEs, most of which were manageable and could be relieved by supportive care or dose reduction, and only 5 (12.5%) patients discontinued treatment due to AEs. Moreover, no life-threatening events were highlighted. Overall, our combination chemotherapy regimen demonstrated a manageable safety profile in patients with aggressive PTCL.

Several limitations need to be acknowledged in our study. Firstly, the lack of randomization makes it impossible to directly compare the efficacy and safety of our regimen with CHOP/CHOP-like or BV-containing regimens. Secondly, the open-label and single-center design might introduce a potential risk of bias. Thirdly, given the fact that PTCL comprises a heterogeneous group of NHLs, each histologic subtype had a limited sample size. Fourthly, patients enrolled in our study have relatively few poor prognostic factors according to previous studies.27,28

In summary, the long-term results from this phase 2 study showed that the combined treatment of PLD, cyclophosphamide, vincristine/vindesine, and prednisone was efficacious in patients with aggressive PTCL with a manageable safety profile, particularly a less cardiotoxicity. Based on these impressive results, this combination regimen might be a promising first-line alternative with a favorable benefit-risk balance for aggressive PTCL. Randomized, multicenter studies with a large sample size are needed to confirm our findings.

Acknowledgment

Author contributions: Jun-Ning Cao is the principal investigator.

Conflicts of interest

The authors have no relevant financial or non-financial interests to disclose.

Data availability

The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.
==== Refs
References

1. Cheson BD , HorningSJ, CoiffierB, et al . Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17 (4 ):1244-1244. 10.1200/jco.1999.17.4.1244 10561185
2. Plana JC , GalderisiM, BaracA, et al . Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imag. 2014;15 (10 ):1063-1093. 10.1093/ehjci/jeu192
3. Wang J , GaoL, QiuH, et al . Comparative study on the efficacy of hyper CVAD/MA regimen and CHOP or CHOP like regimen in the treatment of primary peripheral T cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2014;35 (10 ):897-900.25339325
4. Reimer P , RüdigerT, GeissingerE, et al . Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27 (1 ):106-113. 10.1200/JCO.2008.17.4870 19029417
5. Kangsheng G , DiW, JingjingW. Therapeutic effects and influencing factors in sixty-eight cases of peripheral T-cell lymphoma unspecified. Tumori. 2014;100 (1 ):21-25. 10.1700/1430.15810 24675486
6. Bachy E , CamusV, ThieblemontC, et al . Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40 (3 ):242-251. 10.1200/JCO.21.01815 34843406
7. Advani RH , AnsellSM, LechowiczMJ, et al . A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. Br J Haematol. 2016;172 (4 ):535-544. 10.1111/bjh.13855 26627450
8. Kluin-Nelemans HC , van Marwijk KooyM, LugtenburgPJ, et al . Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22 (7 ):1595-1600. 10.1093/annonc/mdq635 21212158
9. Schmitz N , TrümperL, ZiepertM, et al . Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116 (18 ):3418-3425. 10.1182/blood-2010-02-270785 20660290
10. Horwitz S , O’ConnorOA, ProB, et al. ; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393 (10168 ):229-240. 10.1016/S0140-6736(18)32984-2 30522922
11. Horwitz S , O’ConnorOA, ProB, et al . The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33 (3 ):288-298. 10.1016/j.annonc.2021.12.002 34921960
12. Chen H , TaoY, ZhouY, et al . The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: a single-institution analysis of 240 Chinese patients. Asia Pac J Clin Oncol. 2022;19 (5 ):e202-e214.35821612
13. Gleeson M , PeckittC, ToYM, et al . CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018;5 (5 ):e190-e200. 10.1016/S2352-3026(18)30039-5 29703335
14. Li L , DuanW, ZhangL, et al . The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017;178 (5 ):772-780. 10.1111/bjh.14763 28597542
15. Abouyabis AN , ShenoyPJ, SinhaR, FlowersCR, LechowiczMJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011 :623924. 10.5402/2011/623924 22084700
16. d’Amore F , RelanderT, LauritzsenGF, et al . Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30 (25 ):3093-3099. 10.1200/JCO.2011.40.2719 22851556
17. Horwitz SM , AnsellS, AiWZ, et al . T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20 (3 ):285-308. 10.6004/jnccn.2022.0015 35276674
18. Suzuki Y , YanoT, SuehiroY, et al . Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma. Int J Hematol. 2020;112 (6 ):817-824. 10.1007/s12185-020-02987-7 32886278
19. Shirouchi Y , YokoyamaM, FukutaT, et al . Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. Leuk Lymphoma. 2021;62 (8 ):1869-1876. 10.1080/10428194.2021.1894649 33688781
20. Maurer MJ , EllinF, SrourL, et al . international assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35 (36 ):4019-4026. 10.1200/JCO.2017.73.8195 29072976
21. Pangalis GA , VassilakopoulosTP, MichalisE, et al. ; Hellenic Cooperative Lymphoma Group. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44 (4 ):635-644. 10.1080/1042819031000063471 12769340
22. Wulf GG , AltmannB, ZiepertM, et al ; ACT-2 study investigators. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. 2021;35 (1 ):143-155. 10.1038/s41375-020-0838-5 32382083
23. Nousiainen T , JantunenE, VanninenE, HartikainenJ. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86 (11 ):1697-1700. 10.1038/sj.bjc.6600346 12087452
24. Herbrecht R , CernohousP, EngertA, et al . Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol. 2013;24 (10 ):2618-2623. 10.1093/annonc/mdt289 23946328
25. Mihalcea D , BrujaR, VladareanuA, AndrusE, VinereanuD. P1582 early detection and prediction of CHOP-induced cardiotoxicity through 3D myocardial deformation, arterial stiffness and cardiac biomarkers in non-Hodgkin lymphoma. Eur Heart J. 2018;39 (suppl_1 ):ehy565. P1582.
26. Gottsauner-Wolf M , Schedlmayer-DuitJ, PorentaG, et al . Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis. Eur J Nucl Med. 1996;23 (12 ):1613-1618. 10.1007/BF01249624 8929315
27. International Non-Hodgkin’s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329 (14 ):987-994.8141877
28. Gallamini A , StelitanoC, CalviR, et al. ; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103 (7 ):2474-2479. 10.1182/blood-2003-09-3080 14645001
